SARS-CoV-2 Triggering Severe Acute Respiratory Distress Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in a 3-Year-Old Child With Down Syndrome | Zendy

Sarah Kim-Hellmuth | Zendy; Matthias Hermann | Zendy; Julia Eilenberger | Zendy; Julia LeyZaporozhan | Zendy; Marcus Fischer | Zendy; Fabian Hauck | Zendy; Christoph Klein | Zendy; Nikolaus A. Haas | Zendy; Matthias Kappler | Zendy; Johannes Hüebner | Zendy; André Jakob | Zendy; Ulrich von Both | Zendy

Open Access

SARS-CoV-2 Triggering Severe Acute Respiratory Distress Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in a 3-Year-Old Child With Down Syndrome

Author(s) -

Sarah Kim-Hellmuth,

Matthias Hermann,

Julia Eilenberger,

Julia LeyZaporozhan,

Marcus Fischer,

Fabian Hauck,

Christoph Klein,

Nikolaus A. Haas,

Matthias Kappler,

Johannes Hüebner,

André Jakob,

Ulrich von Both

Publication year - 2020

Publication title -

journal of the pediatric infectious diseases society

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.269

H-Index - 31

eISSN - 2048-7207

pISSN - 2048-7193

DOI - 10.1093/jpids/piaa148

Subject(s) - medicine , hemophagocytic lymphohistiocytosis , acute respiratory distress , covid-19 , respiratory distress , pediatrics , macrophage activation syndrome , ards , immunology , intensive care medicine , virology , lung , disease , surgery , infectious disease (medical specialty) , arthritis , outbreak

Down syndrome (DS) predisposes to severe immunologic reaction secondary to infectious triggers. Here, we report a pediatric DS patient with coronavirus disease 2019 (COVID-19) who developed a hyperinflammatory syndrome, severe acute respiratory distress syndrome, and secondary hemophagocytic lymphohistiocytosis requiring pediatric intensive care unit admission and treatment with steroids, intravenous immunoglobulin, and remdesivir. Investigations into genetic susceptibilities for COVID-19 and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-associated complications warrant systematic clinical and scientific studies. We report a pediatric Down syndrome patient with coronavirus disease 2019 (COVID-19) who developed secondary hemophagocytic lymphohistiocytosis requiring treatment with steroids, intravenous immunoglobulin, and remdesivir. Investigations into genetic susceptibilities for COVID-19-associated complications warrant systematic clinical and scientific studies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research